Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: Eur Urol. 2017 Apr 8;73(2):168–175. doi: 10.1016/j.eururo.2017.03.036

Table 5.

Patients with metastasis (n = 230, 112 with PCSM10)

Model OR (95% CI) p value AUC of model (95% CI) Increase in AUC from adding GC
GC (per 0.1 unit) 1.19 (1.06, 1.34) 0.003 0.63 (0.55, 0.70) (NA)
GC (per 0.1 unit), adjusted for base model 1.19 (1.05, 1.34) 0.006 0.63 (0.56, 0.70) (0.04)
GC (per 0.1 unit), adjusted for CAPRA-S 1.14 (1.01, 1.29) 0.03 0.64 (0.56, 0.70) (0.03)
GC (> 0.6 vs ≤ 0.6) 2.33 (1.37, 3.97) 0.002 0.60 (0.54, 0.67) (NA)
GC (> 0.6 vs ≤ 0.6) + base model 2.31 (1.31, 4.06) 0.004 0.63 (0.56, 0.70) (0.04)
GC (> 0.6 vs ≤ 0.6) + CAPRA-S 1.95 (1.12, 3.39) 0.02 0.64 (0.56, 0.71) (0.03)

AUC = area under the curve; CAPRA-S = Cancer of the Prostate Risk Assessment Postsurgical; CI = confidence interval; GC = Decipher genomic classifier; NA = not applicable; OR = odds ratio; PCSM = prostate cancer-specific mortality.